What drove adapthealth (NASDAQ:AHCO) revenue up 10.9% despite a USD 184.8 million goodwill charge? 03 November 2026 12:35 PM PST Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key highlights. * Net Revenue rose 10.9% to USD 745.6 million, topping the consensus estimate of USD 725.87 million, with 12.8% organic growth. * EPS of USD 0.29 compared with a consensus estimate of negative USD 0.05, while GAAP diluted loss was USD 1.13. * A USD 184.8 million pre-tax Goodwill write down pushed continuing operations to a net loss of USD 167.0 million. * Adjusted EBITDA guidance rose to USD 510 to 525 million; free Cash Flow fell to USD 50 to 75 million. AdaptHealth Corp. (NASDAQ:AHCO) reported third quarter 2026 net revenue of USD 745.6 million, up 10.9% from USD 672.4 million a year earlier and above a consensus estimate of USD 725.87 million. Organic revenue growth was 12.8%, with growth in each reportable segment. EPS of USD 0.29 compared with a consensus estimate of negative USD 0.05, while GAAP diluted loss per share was USD 1.13, including a loss of USD 1.23 from continuing operations and income of USD 0.10 from discontinued operations. Net loss attributable to the company from continuing operations was USD 168.2 million against Net Income of USD 10.2 million a year earlier. Goodwill charge and margin compression mask revenue growth. The USD 184.8 million non-cash goodwill Impairment stemmed from fair values of the Respiratory Health and Wellness at Home reporting units falling below carrying values. Adjusted EBITDA was USD 141.9 million against USD 146.1 million, a 2.9% decline, and the adjusted margin was 19.0% against 21.7%. Cost of net revenue rose to USD 630.8 million from USD 533.8 million. Chief Executive Officer Suzanne Foster said the company exceeded its own guidance for revenue, adjusted EBITDA and free cash flow, and said the exclusive capitated agreement with a large national integrated delivery network made a positive contribution, helped by a tighter labor model and lower costs to serve. Registered myAPP users passed 615,000, up about 88% from year end 2025. Revised 2026 guidance and the Diabetes Health sale. The company raised its fiscal 2026 net revenue guidance to USD 2.88 to 2.90 billion from USD 2.85 to 2.89 billion, and adjusted EBITDA guidance to USD 510 to 525 million from USD 490 to 520 million. Free cash flow guidance was lowered to USD 50 to 75 million from USD 80 to 120 million. These figures are on a continuing operations basis that excludes the Diabetes Health business, except for free cash flow. The company cleared the Hart-Scott-Rodino Waiting Period for the sale of Diabetes Health for USD 235.0 million in cash, with closing targeted for early 2027 subject to regulatory approvals and customary conditions. Nine month actuals against revised guidance. Nine month net revenue of USD 2.166 billion compares with full year guidance of USD 2.88 to 2.90 billion, which leaves roughly USD 714 to 734 million for the fourth quarter against USD 745.6 million in the third. Nine month adjusted EBITDA of USD 378.5 million against guidance of USD 510 to 525 million leaves roughly USD 131.5 to 146.5 million, against USD 141.9 million in the third quarter. Free cash flow of USD 2.6 million through September compares with USD 140.1 million a year earlier and guidance of USD 50 to 75 million. Long Term Debt less current portion stood at USD 1.868 billion against USD 1.716 billion at year end 2025, while cash fell to USD 80.7 million from USD 106.1 million. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

AdaptHealth reported third-quarter revenue of $745.6 million, up 10.9% from a year earlier and ahead of its guidance. Adjusted EBITDA was $141.9 million, and free cash flow was $51.1 million. Its largest capitated contract drove the gain. The contract's margin rose to about 10% from negative 4% in the second quarter, helped by lower utilisation, reduced capital spending, and staffing cuts. The company targets a 20% margin by the fourth quarter of 2027. AdaptHealth raised full-year revenue guidance to $2.88 billion–$2.9 billion and adjusted EBITDA guidance to $510 million–$525 million. It cut free cash flow guidance to $55 million–$80 million. It expects to use proceeds from the sale of its Diabetes Health business to Cardinal Health, due to close early in 2027, to reduce debt.

AdaptHealth names Currie CFO as growth push takes shape. PLYMOUTH MEETING, PA - AdaptHealth Corp. (Nasdaq: AHCO) named former Luminex finance chief Harriss T. Currie as chief financial officer, putting a veteran health-care executive in charge of its finances as the company targets revenue and EBITDA growth. Currie succeeds Jason Clemens, who will remain with the home medical equipment and supplies provider through Oct. 1 to assist with the transition, AdaptHealth said. Currie spent more than 15 years as CFO of Luminex Corp. before the diagnostics company was sold to DiaSorin in 2021. He later served as CFO of Impulse Dynamics from 2022 to 2023 and president of the Regenerative Medicine division of 3D Systems (NYSE: DDD) from 2023 to 2025. He was CFO of Health Track Rx from 2025 to 2026. Discover more Book Walking Tours Access Premium News The appointment gives Currie responsibility for AdaptHealth's finance organization as the company seeks to translate strategic contracts into revenue and earnings growth. Currie said his assessment of the company before taking the position found "solid financial processes" and contracts that he believes position AdaptHealth for "meaningful revenue and EBITDA growth." Chief Executive Officer Suzanne Foster said Currie will inherit a finance team and organizational structure established under Clemens. AdaptHealth provides home medical equipment, medical supplies and related health-care-at-home services. Currie previously worked as an audit manager at Deloitte & Touche. He holds an MBA from the University of Texas at Austin's McCombs School of Business. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today. Discover more Read Community News Claim Your Listing Book Walking Tours